Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Active not recruiting 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

pembrolizumab 2erdafitinib 2Gemcitabine 2Cisplatin 2Carboplatin 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Tiragolumab 1Midazolam 1Metformin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Urothelial Cancer × 90 days × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting
629 enrolled 32 charts
Genitourinary

Urothelial Cancer

NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
204 enrolled
Genitourinary

Urothelial Cancer

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡